CD33 and acute myeloid leukemia: explored the use of controlled anti-CD33 CAR-T cells (SC-DARIC33), genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) controlled by post-infusion intermittent doses of rapamycin in a phase I trial in pediatric and young adult patients with R/R CD33+ AML (NCT05105152).